This article explores a novel CAR engineering strategy that enhances the effectiveness of CAR-T cell therapy. The strategy focuses on incorporating a modified intracellular domain that boosts antigen sensitivity and cytotoxic activity, overcoming existing limitations in cancer treatment.
